US Stock MarketDetailed Quotes

GYRE Gyre Therapeutics

Watchlist
  • 13.840
  • -0.640-4.42%
Close Nov 14 16:00 ET
1.19BMarket Cap-9479P/E (TTM)

About Gyre Therapeutics Company

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.

Company Profile

SymbolGYRE
Company NameGyre Therapeutics
Listing DateApr 12, 2006
Founded1997
CEODr. Han Ying, PhD
MarketNASDAQ
Employees4
Fiscal Year Ends12-31
Address12770 High Bluff Drive,Suite 150
CitySan Diego
ProvinceCalifornia
CountryUnited States of America
Zip Code92130
Phone1-619-949-3681
Websitehttp://www.gyretx.com

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Han Ying, PhD
  • Director and Chief Executive Officer
  • --
  • Ruoyu Chen
  • Chief Financial Officer and Principal Accounting Officer
  • --
  • Weiguo Ye
  • Chief Operating Officer
  • --
  • Dr. Ying Luo, PhD
  • Chairman of the Board
  • --
  • Songjiang Ma
  • Director and President
  • --
  • Dr. David M. Epstein, PhD
  • Director
  • --
  • Rodney L. Nussbaum
  • Director
  • --
  • Thomas Eastling
  • Director
  • --
  • Dr. Gordon G. Carmichael, PhD
  • Independent Director
  • --
  • Dr. Renate Parry, PhD
  • Independent Director
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data